Hypertrophic Cardiomyopathy Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Hypertrophic Cardiomyopathy Therapeutics Market is segmented by Drug Class (Antiarrhythmic Agents, Anticoagulants, Beta Adrenergic Blocking Agents, Calcium Channel Blockers, Others) and Geography.

Market Snapshot

CAGR
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 1.8 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

Hypertrophic cardiomyopathy (HCM) is a genetic heart muscle disease caused by a mutation in sarcomere protein genes which encodes for the contractile machinery of the heart which is characterized by an increase in left ventricular wall thickness which causes left ventricular outflow obstruction, diastolic dysfunction, myocardial ischemia, and mitral regurgitation. Symptoms of the hypertrophic cardiomyopathy are fatigue, dyspnea, chest pain, palpitations, and syncope. 

According to the World Health Organization (WHO), an estimated 17.9 million people died from cardiovascular diseases in the year 2016, which accounts 31% of all global deaths. Increase in obese and sedentary lifestyle population, increasing cases of cardiac diseases are the major driving factors in the hypertrophic cardiomyopathy therapeutics market.

Scope of the Report

As per the scope of the report, Hypertrophic cardiomyopathy is a genetic heart muscle disease caused by a mutation in sarcomere protein genes which encodes for the contractile machinery of the heart. 

By Drug Class
Antiarrhythmic Agents
Anticoagulants
Beta Adrenergic Blocking Agents
Calcium Channel Blockers
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Calcium Channel Blockers Segment is Expected to Hold a Major Market Share in Hypertrophic Cardiomyopathy Therapeutics Market

Calcium channel blockers or calcium channel antagonists or calcium antagonists are most commonly used as antihypertensive drugs which act by reducing the amount of calcium that goes into the cardiac muscle cells and cause them to relax. Calcium channel blockers are used to alter the heart rate, reduce chest pain, and to prevent cerebral vasospasm more effective compared to beta-blockers in the treatment of cardiovascular disorders. Furthermore, rising geriatric population and obesity are also the major factors driving the market.

Obesity.png

North America is Expected to Dominate the Market and Expected to do Same in the Forecast Period

North America expected to hold significant market share in the global hypertrophic cardiomyopathy (HCM) market due to the rising prevalence of congestive heart failure, sedentary lifestyles of individuals in the united states. 

As per The Centers for Disease Control and Prevention (CDC), more than five million people are suffering from heart failure diseases in the United States, and about half of the affected population die within five years of diagnosis. Moreover, the existence of a developed healthcare care system and affordable reimbursement policies for the treatment of cardiovascular diseases is anticipated to positively reinforce the growth.

Hypertrophic Cardiomyopathy Therapeutics Market 2

Competitive Landscape

The Hypertrophic Cardiomyopathy Therapeutics Market is moderately consolidated competitive and consists of of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently domianting the market are Sanofi S.A., Astra Zeneca Plc, Pfizer Inc, ADVANZ PHARMA Corp (Concordia Healthcare Corp), Gilead Sciences Inc, Merck & Co., Inc, Teva Pharmaceutical Industries Ltd, Novartis AG, Mylan N.V., Bayer AG.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rise in Obese and Sedentary Lifestyle Population

      2. 4.2.2 New Product Development for Targeted Cardiac Disorders

    3. 4.3 Market Restraints

      1. 4.3.1 Technological Advancement in Devices

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug Class

      1. 5.1.1 Antiarrhythmic Agents

      2. 5.1.2 Anticoagulants

      3. 5.1.3 Beta Adrenergic Blocking Agents

      4. 5.1.4 Calcium Channel Blockers

      5. 5.1.5 Others

    2. 5.2 Geography

      1. 5.2.1 North America

        1. 5.2.1.1 United States

        2. 5.2.1.2 Canada

        3. 5.2.1.3 Mexico

      2. 5.2.2 Europe

        1. 5.2.2.1 Germany

        2. 5.2.2.2 United Kingdom

        3. 5.2.2.3 France

        4. 5.2.2.4 Italy

        5. 5.2.2.5 Spain

        6. 5.2.2.6 Rest of Europe

      3. 5.2.3 Asia-Pacific

        1. 5.2.3.1 China

        2. 5.2.3.2 Japan

        3. 5.2.3.3 India

        4. 5.2.3.4 Australia

        5. 5.2.3.5 South Korea

        6. 5.2.3.6 Rest of Asia-Pacific

      4. 5.2.4 Middle-East and Africa

        1. 5.2.4.1 GCC

        2. 5.2.4.2 South Africa

        3. 5.2.4.3 Rest of Middle-East and Africa

      5. 5.2.5 South America

        1. 5.2.5.1 Brazil

        2. 5.2.5.2 Argentina

        3. 5.2.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Astra Zeneca Plc

      2. 6.1.2 ADVANZ PHARMA Corp (Concordia Healthcare Corp)

      3. 6.1.3 Bayer AG

      4. 6.1.4 Gilead Sciences, Inc

      5. 6.1.5 Merck & Co., Inc

      6. 6.1.6 Mylan N.V.

      7. 6.1.7 Novartis AG

      8. 6.1.8 Pfizer, Inc

      9. 6.1.9 Sanofi S.A.

      10. 6.1.10 Teva Pharmaceutical Industries Ltd

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Hypertrophic Cardiomyopathy Therapeutics Market market is studied from 2018 - 2026.

The Hypertrophic Cardiomyopathy Therapeutics Market is growing at a CAGR of 1.8% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

AstraZeneca Plc, Bayer AG, Sanofi S.A., Merck & Co., Inc, Novartis AG are the major companies operating in Hypertrophic Cardiomyopathy Therapeutics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!